Latest filing published 14 Nov 2022 for Roivant Sciences Ltd., €20.0M.
Filing timeline
BuySaleInsider track record
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Dexcel Pharma Technologies Ltd.: trading record in brief
Dexcel Pharma Technologies Ltd. discloses dealings in 3 companies, chiefly Intec Pharma Ltd., Roivant Sciences Ltd. and Protalix BioTherapeutics, Inc. We count 8 filings; the first trade dates from 31 January 2020 and the latest from 10 November 2022.
Market trades split into 3 purchases (€20.1M) and 5 sales (€2.0M). On balance, insiders were net buyers of €18.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2022 alone, the filings show 3 purchases and no sales.
In size, the median ticket on the buying side is €112k. No cluster: in 3 purchases, no other insider of the company bought within 30 days.
Most recently, on 14 November 2022, the filings show an open-market purchase worth €20.0M in Roivant Sciences Ltd. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Dexcel Pharma Technologies Ltd.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,000,000 shares@ US$5.0099.4% of flowCommon SharesSEC:0001104659-22-117847:0Canonical exit: 8 Feb 2023 (T+90)
- 31,685 shares@ US$3.82890.0005% mcap100.0% of flowCommon SharesSEC:0001104659-22-049930:0Canonical exit: 21 Jul 2022 (T+90)
- 61,211 shares@ US$2.5576100.0% of flowCommon StockSEC:0001104659-21-076488:0
3 of 3 declarations
